| 摘要 |
The invention relates to novel arylalkyl- or aryloxyalkyl-substituted oxiranecarboxyclic acids of the general formula I in which Ar, R3, Y and n are as defined in the description, and also to medicaments comprising them and to their use for the treatment and prophylaxis of the disorders mentioned in the description [in claim 4] which are caused by disturbances of glucose and/or lipid metabolism, such as, for example diabetes type 2, and other insulin-resistant conditions.
|
